Literature DB >> 17475713

Reduced expression of autotaxin predicts survival in uveal melanoma.

Arun D Singh1, Karen Sisley, Yaomin Xu, Jianbo Li, Pieter Faber, Sarah J Plummer, Hardeep S Mudhar, Ian G Rennie, Patricia M Kessler, Graham Casey, Bryan G Williams.   

Abstract

AIM: In an effort to identify patients with uveal melanoma at high risk of metastasis, the authors undertook correlation of gene expression profiles with histopathology data and tumour-related mortality.
METHODS: The RNA was isolated from 27 samples of uveal melanoma from patients who had consented to undergo enucleation, and transcripts profiled using a cDNA array comprised of sequence-verified cDNA clones representing approximately 4000 genes implicated in cancer development. Two multivariate data mining techniques--hierarchical cluster analysis and multidimensional scaling--were used to investigate the grouping structure in the gene expression data. Cluster analysis was performed with a subset of 10,000 randomly selected genes and the cumulative contribution of all the genes in making the correct grouping was recorded.
RESULTS: Hierarchical cluster analysis and multidimensional scaling revealed two distinct classes. When correlated with the data on metastasis, the two molecular classes corresponded very well to the survival data for the 27 patients. Thirty two discrete genes (corresponding to 44 probe sets) that correctly defined the molecular classes were selected. A single gene (ectonucleotide pyrophosphatase/phosphodiesterase 2; autotaxin) could classify the molecular types. The expression pattern was confirmed using real-time quantitative PCR.
CONCLUSIONS: Gene expression profiling identifies two distinct prognostic classes of uveal melanoma. Underexpression of autotaxin in class 2 uveal melanoma with a poor prognosis needs to be explored further.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475713      PMCID: PMC2001033          DOI: 10.1136/bjo.2007.116947

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  48 in total

1.  Nonrandom chromosomal abnormalities in primary uveal melanoma.

Authors:  G Prescher; N Bornfeld; R Becher
Journal:  J Natl Cancer Inst       Date:  1990-11-21       Impact factor: 13.506

2.  Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis.

Authors:  K Sisley; I G Rennie; M A Parsons; R Jacques; D W Hammond; S M Bell; A M Potter; R C Rees
Journal:  Genes Chromosomes Cancer       Date:  1997-05       Impact factor: 5.006

3.  The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18.

Authors:  M Diener-West; J D Earle; S L Fine; B S Hawkins; C S Moy; S M Reynolds; A P Schachat; B R Straatsma
Journal:  Arch Ophthalmol       Date:  2001-07

4.  Prognostic implications of monosomy 3 in uveal melanoma.

Authors:  G Prescher; N Bornfeld; H Hirche; B Horsthemke; K H Jöckel; R Becher
Journal:  Lancet       Date:  1996-05-04       Impact factor: 79.321

Review 5.  Uveal melanoma.

Authors:  M R Conlon; D M Albert
Journal:  Int Ophthalmol Clin       Date:  1993

6.  Cytogenetic findings in primary uveal melanoma.

Authors:  A D Singh; L Boghosian-Sell; K K Wary; C L Shields; P De Potter; L A Donoso; J A Shields; L A Cannizzaro
Journal:  Cancer Genet Cytogenet       Date:  1994-02

7.  A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988.

Authors:  M Diener-West; B S Hawkins; J A Markowitz; A P Schachat
Journal:  Arch Ophthalmol       Date:  1992-02

8.  The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study.

Authors:  R Folberg; J Pe'er; L M Gruman; R F Woolson; G Jeng; P R Montague; T O Moninger; H Yi; K C Moore
Journal:  Hum Pathol       Date:  1992-11       Impact factor: 3.466

9.  Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein.

Authors:  M L Stracke; H C Krutzsch; E J Unsworth; A Arestad; V Cioce; E Schiffmann; L A Liotta
Journal:  J Biol Chem       Date:  1992-02-05       Impact factor: 5.157

10.  The prognostic value of tumor blood vessel morphology in primary uveal melanoma.

Authors:  R Folberg; V Rummelt; R Parys-Van Ginderdeuren; T Hwang; R F Woolson; J Pe'er; L M Gruman
Journal:  Ophthalmology       Date:  1993-09       Impact factor: 12.079

View more
  13 in total

1.  Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma.

Authors:  Mandi M Murph; Guowei W Jiang; Molly K Altman; Wei Jia; Duy T Nguyen; Jada M Fambrough; William J Hardman; Ha T Nguyen; Sterling K Tran; Ali A Alshamrani; Damian Madan; Jianxing Zhang; Glenn D Prestwich
Journal:  Bioorg Med Chem       Date:  2015-07-02       Impact factor: 3.641

2.  Are Risk Factors for Growth of Choroidal Nevi Associated With Malignant Transformation? Assessment With a Validated Genomic Biomarker.

Authors:  J William Harbour; Manuel Paez-Escamilla; Louis Cai; Scott D Walter; James J Augsburger; Zelia M Correa
Journal:  Am J Ophthalmol       Date:  2018-09-07       Impact factor: 5.258

3.  BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas.

Authors:  Matthew G Field; Jeffim N Kuznetsov; Parker L Bussies; Louie Z Cai; Karam A Alawa; Christina L Decatur; Stefan Kurtenbach; J William Harbour
Journal:  Clin Cancer Res       Date:  2019-07-08       Impact factor: 12.531

4.  Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; Devron H Char; James J Augsburger; Zelia M Correa; Eric Nudleman; Thomas M Aaberg; Michael M Altaweel; David S Bardenstein; Paul T Finger; Brenda L Gallie; George J Harocopos; Peter G Hovland; Hugh D McGowan; Tatyana Milman; Prithvi Mruthyunjaya; E Rand Simpson; Morton E Smith; David J Wilson; William J Wirostko; J William Harbour
Journal:  Ophthalmology       Date:  2012-04-21       Impact factor: 12.079

5.  An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; Meghan D Tuscan; J William Harbour
Journal:  J Mol Diagn       Date:  2010-04-22       Impact factor: 5.568

6.  Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.

Authors:  Marion David; Estelle Wannecq; Françoise Descotes; Silvia Jansen; Blandine Deux; Johnny Ribeiro; Claire-Marie Serre; Sandra Grès; Nathalie Bendriss-Vermare; Mathieu Bollen; Simone Saez; Junken Aoki; Jean-Sébastien Saulnier-Blache; Philippe Clézardin; Olivier Peyruchaud
Journal:  PLoS One       Date:  2010-03-17       Impact factor: 3.240

7.  Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes.

Authors:  Christina L Decatur; Erin Ong; Nisha Garg; Hima Anbunathan; Anne M Bowcock; Matthew G Field; J William Harbour
Journal:  JAMA Ophthalmol       Date:  2016-07-01       Impact factor: 7.389

8.  Prognostic Implications of Tumor Diameter in Association With Gene Expression Profile for Uveal Melanoma.

Authors:  Scott D Walter; Daniel L Chao; William Feuer; Joyce Schiffman; Devron H Char; J William Harbour
Journal:  JAMA Ophthalmol       Date:  2016-07-01       Impact factor: 7.389

9.  Expression profiling of formalin-fixed paraffin embedded primary human uveal melanomas using DASL matrices.

Authors:  Sebastian Di Cesare; Andre Nantel; Jean-Claude Marshall; Bruno F Fernandes; Emilia Antecka; Maria E Orellana; Daniel Abourbih; Antonia M Saornil; Miguel N Burnier
Journal:  J Cancer Res Clin Oncol       Date:  2009-10-13       Impact factor: 4.553

Review 10.  Autotaxin.

Authors:  Jean A Boutin; Gilles Ferry
Journal:  Cell Mol Life Sci       Date:  2009-06-09       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.